CR20130138A - Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación - Google Patents

Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación

Info

Publication number
CR20130138A
CR20130138A CR20130138A CR20130138A CR20130138A CR 20130138 A CR20130138 A CR 20130138A CR 20130138 A CR20130138 A CR 20130138A CR 20130138 A CR20130138 A CR 20130138A CR 20130138 A CR20130138 A CR 20130138A
Authority
CR
Costa Rica
Prior art keywords
preparation
formula
intermediaries
pan
cdk inhibitors
Prior art date
Application number
CR20130138A
Other languages
English (en)
Inventor
Joachim Krueger
Joerg Gries
Kai Lovis
Jorma Hassfeld
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44677881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20130138(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CR20130138A publication Critical patent/CR20130138A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/10—Compounds containing sulfur atoms doubly-bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Nuevo proceso para la preparación de inhibidores depan-CDK de la fórmula (I), e intermediarios que seutilizan en la preparación.
CR20130138A 2010-09-23 2013-03-22 Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación CR20130138A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102010046720A DE102010046720A1 (de) 2010-09-23 2010-09-23 Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung

Publications (1)

Publication Number Publication Date
CR20130138A true CR20130138A (es) 2013-05-15

Family

ID=44677881

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130138A CR20130138A (es) 2010-09-23 2013-03-22 Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación

Country Status (32)

Country Link
US (1) US9359306B2 (es)
EP (1) EP2619186A1 (es)
JP (1) JP5969993B2 (es)
KR (1) KR20130109145A (es)
CN (1) CN103119026B (es)
AP (1) AP2013006816A0 (es)
AR (1) AR083171A1 (es)
AU (1) AU2011304365B2 (es)
BR (1) BR112013006720A2 (es)
CA (1) CA2811807A1 (es)
CL (1) CL2013000797A1 (es)
CO (1) CO6690779A2 (es)
CR (1) CR20130138A (es)
CU (2) CU20130044A7 (es)
DE (1) DE102010046720A1 (es)
DO (1) DOP2013000063A (es)
EC (1) ECSP13012520A (es)
GT (1) GT201300078A (es)
IL (1) IL225352A0 (es)
MX (1) MX2013003338A (es)
MY (1) MY160625A (es)
NZ (1) NZ608448A (es)
PE (1) PE20140182A1 (es)
PH (1) PH12013500554A1 (es)
RU (1) RU2585621C2 (es)
SA (1) SA111320775B1 (es)
SG (1) SG188967A1 (es)
TW (1) TWI530488B (es)
UA (1) UA110626C2 (es)
UY (1) UY33624A (es)
WO (1) WO2012038411A1 (es)
ZA (1) ZA201301799B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
WO2014173815A1 (en) * 2013-04-23 2014-10-30 Bayer Pharma Aktiengesellschaft Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours
PL3692039T3 (pl) 2017-10-05 2023-04-17 Innovative Molecules Gmbh Enancjomery podstawionych tiazoli jako związki przeciwwirusowe
US11701347B2 (en) 2018-02-13 2023-07-18 Bayer Aktiengesellschaft Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large B-cell lymphoma
KR20250168210A (ko) 2023-02-16 2025-12-02 가셔브룸 바이오, 인크. 헤테로시클릭 glp-1 효능제
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118481A (en) * 1995-06-05 2000-08-31 Rhone Poulenc Agrochimie Sulfur compounds pesticidal compositions containing them and method of their application
EP1291336A3 (en) 2001-09-05 2003-10-08 Solvias AG Preparation of optically active alpha-hydroxyethers
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102005062742A1 (de) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
EP2022785A1 (en) * 2007-06-20 2009-02-11 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines as Tie2 kinase inhibitors
EP2179991A1 (de) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
BR112013006720A2 (pt) 2016-06-14
AR083171A1 (es) 2013-02-06
ZA201301799B (en) 2014-05-28
AP2013006816A0 (en) 2013-04-30
EP2619186A1 (de) 2013-07-31
JP5969993B2 (ja) 2016-08-17
PH12013500554A1 (en) 2013-05-06
JP2013542189A (ja) 2013-11-21
CO6690779A2 (es) 2013-06-17
UY33624A (es) 2012-04-30
SG188967A1 (en) 2013-05-31
MY160625A (en) 2017-03-15
WO2012038411A1 (de) 2012-03-29
CN103119026A (zh) 2013-05-22
CU20150165A7 (es) 2016-05-30
PE20140182A1 (es) 2014-02-14
MX2013003338A (es) 2013-06-24
NZ608448A (en) 2014-10-31
CA2811807A1 (en) 2012-03-29
US20130245261A1 (en) 2013-09-19
UA110626C2 (uk) 2016-01-25
RU2013118432A (ru) 2014-10-27
RU2585621C2 (ru) 2016-05-27
AU2011304365A1 (en) 2013-04-11
KR20130109145A (ko) 2013-10-07
CN103119026B (zh) 2015-08-19
TW201215596A (en) 2012-04-16
DOP2013000063A (es) 2013-04-30
SA111320775B1 (ar) 2015-02-03
CU20130044A7 (es) 2013-07-31
ECSP13012520A (es) 2013-05-31
CL2013000797A1 (es) 2013-09-13
AU2011304365B2 (en) 2015-02-05
HK1185615A1 (en) 2014-02-21
DE102010046720A1 (de) 2012-03-29
US9359306B2 (en) 2016-06-07
IL225352A0 (en) 2013-06-27
GT201300078A (es) 2014-11-26
TWI530488B (zh) 2016-04-21

Similar Documents

Publication Publication Date Title
DOP2013000063A (es) Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación
CL2017002283A1 (es) Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)
SV2010003718A (es) Inhibidores de bace
TN2011000673A1 (en) Bace inhibitors
UA114901C2 (uk) Інгібітори асс та їх застосування
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
CR20140529A (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
MX2015013202A (es) Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
CL2012003385A1 (es) Tratamiento para la incontinencia.
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
UY33958A (es) Inhibidores de la glucosilceramida sintasa
BR112013004490A2 (pt) aparelho para medir propriedade termodinâmicas de fluidos de reservatório, e método para medir propriedades termodinâmicas de fluidos de reservatório
ECSP088961A (es) Nuevos herbicidas
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
UA116920C2 (uk) Інгібітори fgfr4
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
UY34037A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
UY33930A (es) Inhibidores novedosos de quinasas
CO7091177A2 (es) Inhibidores de la beta-secretasa
UY34661A (es) Inhibidores de benzodioxano de la producción de leucotrieno para terapia de combinación
BR112014011254A2 (pt) 2-tiopirimidinonas
DOP2012000260A (es) Uso de nuevos inhibidores de pan–cdk para tratar tumores
MX372739B (es) Metodos y composiciones para inhibir cnksr1.
UY34277A (es) Metodo para la eliminación del naftaleno